Knowledge Library

High-Quality and Cost-Effective Plasmid Platform

In recent years, the demand for cell and gene therapy has increased substantially. The success in gene and cell therapy has also increased demand for plasmid DNA. In supplying the industry with high-quality plasmid DNA, key prominent market challenges are capacity availability, accelerated turnaround time (TAT), and affordability. In this presentation, WuXi Advanced Therapies will …Read More >

Resource Type: Webinar
Resource Topic: Advanced Testing Clinical & Commercial Manufacturing

VIEW

Lentiviral Vector Platform Generation: Increase titer and yield with greater predictability

The field of gene and cell therapies expand rapidly in the past several years. Lentiviral vectors have been in a great demand as gene carriers in this field, especially for ex vivo gene therapies. However, the large scale lentiviral vector production still remains significant challenges. WuXi Advanced Therapies have experience working with Lentivirus since 2015 …Read More >

Resource Type: Webinar
Resource Topic: Clinical & Commercial Manufacturing

VIEW

WuXi Webinar on Spinal Muscular Atrophy

In order to promote the public’s awareness of rare diseases and showcase WuXi AppTec’s positive social impact, on Aug. 20, we organized a 3-session webinar series on Spinal Muscular Atrophy, including a fireside chat between Dr. David Chang, CEO of WuXi ATU, and Paulo Fontoura, Global Head and SVP, Neuroscience and Rare Diseases Clinical Development …Read More >

Resource Type: Webinar
Resource Topic: Clinical & Commercial Manufacturing

VIEW

Innovative Closed Process CAR-T cell therapy platform to streamline approach for manufacturing with great predictability

Date: May 19, 2020 Time: 11 am EDT | 8 am PDT | 5 pm CEST For many years, the primary forms of cancer treatment have been chemotherapy, radiation, and surgery. An amazing breakthrough known as chimeric antigen receptor (CAR) T-cell therapy is being studied in the treatment of various types of cancer, including acute and …Read More >

Resource Type: Webinar
Resource Topic: Clinical & Commercial Manufacturing

VIEW

World-class AAV vector suspension platform to accelerate commercialization to market with greater predictability

WuXi Advanced Therapies launched a new world-class adenoassociated virus (AAV) vector suspension platform that complements integrated capabilities enabling cell and gene therapies to be developed, manufactured, and released faster and with greater predictability globally.

Resource Type: Webinar
Resource Topic: Clinical & Commercial Manufacturing

VIEW